Abstract: The presently disclosed invention relates to products and methods of treating cancer in a patient comprising administering to the patient a pharmaceutically therapeutic dose of a chemotherapeutic, or any pharmaceutically acceptable salt, solvate, or prodrug thereof, conjugated to a nanocarrier. According to a further embodiment, the chemotherapeutic has a primary (10) amine (—NH2) group in within a pharmaceutical structure of the chemotherapeutic structure. According to a further embodiment, the chemotherapeutic is one of a platinum-based pharmaceutical and an Anthracycline family pharmaceutical. According to a further embodiment, the chemotherapeutic is one of gemcitabine, methotrexate, cisplatin, oxaliplatin, doxorubicin, daunorubicine, idarubicine, and epirubicine. According to a further embodiment, the chemotherapeutic is either attached to the nanocarrier by means that includes covalent bonds or is attached by means that does not included covalent bonds.

Abstract: Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.